\begin{tabular*}{\textwidth}{@{\extracolsep\fill}clllllllllll@{\extracolsep\fill}}
\toprule
&  & \multicolumn{3}{c}{Final Selection (\%)$^1$} & \multicolumn{3}{c}{Allocations (\%)} & &  &  &  \\
\multirow{2}{2em}{Alpha} & \multirow{2}{2em}{Method} & \multirow{2}{2em}{MTD} & \multirow{2}{2em}{Above MTD} & \multirow{2}{2em}{Below MTD} & \multirow{2}{2em}{MTD} & \multirow{2}{2em}{Above MTD} & \multirow{2}{2em}{Below MTD} & \multirow{2}{2em}{Toxic~\%$^2$} & \multirow{2}{2em}{DLTs} & \multirow{2}{2em}{Trial Size} & \multirow{2}{2em}{Days}  \\ \\ 
\midrule
\multirow{4}{2em}{0} & CRM & 42 & 18 & 40 & 26 & 25 & 49 & 43 & 7.5 & 27.4 & 395\\
 & AIDE-CRM & 42 & 20 & 39 & 26 & 25 & 49 & 42 & 7.4 & 23.1 & 333\\
 & $\alpha$-CRM & 42 & 24 & 34 & 25 & 27 & 47 & 43 & 7.5 & 22.9 & 330\\
 & IPDE-POCRM & 44 & 27 & 29 & 26 & 29 & 45 & 44 & 7.6 & 22.4 & 323\\
\midrule
\multirow{4}{2em}{0.3} & CRM & 41 & 19 & 40 & 26 & 25 & 49 & 43 & 7.5 & 27.5 & 395\\
 & AIDE-CRM & 41 & 17 & 42 & 25 & 24 & 51 & 43 & 7.5 & 23.1 & 332\\
 & $\alpha$-CRM & 43 & 22 & 35 & 26 & 26 & 48 & 44 & 7.7 & 22.9 & 330\\
 & IPDE-POCRM & 44 & 24 & 32 & 26 & 28 & 46 & 45 & 7.9 & 22.5 & 323\\
\midrule
\multirow{4}{2em}{0.6} & CRM & 41 & 19 & 40 & 26 & 25 & 49 & 43 & 7.5 & 27.5 & 395\\
 & AIDE-CRM & 39 & 15 & 46 & 25 & 23 & 52 & 44 & 7.7 & 23.2 & 334\\
 & $\alpha$-CRM & 42 & 20 & 38 & 26 & 25 & 49 & 45 & 7.9 & 23.0 & 330\\
 & IPDE-POCRM & 44 & 21 & 35 & 26 & 27 & 47 & 47 & 8.0 & 22.4 & 323\\
\midrule
\multirow{4}{2em}{0.9} & CRM & 42 & 18 & 40 & 26 & 25 & 49 & 43 & 7.5 & 27.5 & 396\\
 & AIDE-CRM & 37 & 13 & 50 & 24 & 22 & 54 & 45 & 7.8 & 23.2 & 334\\
 & $\alpha$-CRM & 41 & 17 & 42 & 25 & 24 & 51 & 46 & 8.1 & 23.1 & 332\\
 & IPDE-POCRM & 42 & 18 & 40 & 26 & 25 & 49 & 48 & 8.3 & 22.6 & 325\\
\bottomrule
\end{tabular*}
